CDC headed to losing credibility, biosafety experts charge

It's no surprise the US Centers for Disease Control and Prevention (CDC) was not eager to make public a scathing report from a panel of outside expert advisers that condemned the agency's laboratory safety practices – declaring it "is on the way to losing credibility" after a series of near-calamities involving anthrax, the H5N1 influenza virus and Ebola.

It's no surprise the US Centers for Disease Control and Prevention (CDC) was not eager to make public a scathing report from a panel of outside expert advisers that condemned the agency's laboratory safety practices – declaring it "is on the way to losing credibility" after a series of near-calamities involving anthrax, the H5N1 influenza virus and Ebola.

An 11-member external laboratory safety workgroup (ELSW) of the advisory committee to CDC Director Dr Thomas Frieden delivered the report...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.